Axsome Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Axsome Therapeutics Inc. following an internal corporate realignment.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have filed an amended Schedule 13G, disclosing a 3.1% beneficial ownership stake in Axsome Therapeutics, Inc.
NASDAQ
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a continued beneficial ownership of 6.0% in Axsome Therapeutics, Inc. common stock.
NASDAQ
SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 8.4% Passive Stake in Axsome Therapeutics
RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a passive 8.4% beneficial ownership stake in Axsome Therapeutics, Inc. as of December 31, 2024.